BioTuesdays

Tag - BTIG

Aerovate Therapeutics
Markets

BTIG ups Aerovate to buy on competitor data

BTIG upgraded Aerovate Therapeutics (NASDAQ:AVTE) to “buy” from “neutral” with a $27 price target, citing Gossamer Bio’s TORREY results that could validate Aerovate’s dry powder inhalation (DPI) administered tyrosine...

December 6, 2022
Cullinan Logo
Markets

BTIG starts Cullinan Oncology at buy; PT $20

BTIG initiated coverage of Cullinan Oncology (NASDAQ:CGEM) with a “buy” rating and price target of $20, citing a burgeoning pipeline and unique biology that could open avenues for a broad range of opportunities. The...

November 21, 2022
Annexon Logo
Markets

BTIG starts Annexon at buy; PT $15

BTIG initiated coverage of Annexon (NASDAQ:ANNX) with a “buy” rating and $15 price target. The stock closed at $6.02 on Sept. 8. Annexon, Inc. is a development-stage biotech company focused on mediating the role of...

September 9, 2022
Pear Therapeutics
Markets

BTIG cuts Pear Therapeutics PT to $5 on Q2 results

BTIG reduced its price target for Pear Therapeutics (NASDAQ:PEAR) to $5 from $11 but maintained its “buy” rating after the company missed second quarter revenue consensus and lowered 2022 revenue guidance. The stock...

August 12, 2022
Keros Therapeutics Logo
Markets

BTIG starts Keros at buy; PT $80

BTIG launched coverage of Keros Therapeutics (NASDAQ:KROS) with a “buy” rating and $80 price target. The stock closed at $28.53 on July 25. Analyst Julian Harrison writes that following Acceleron’s impressive foray into...

July 26, 2022
Akoya Logo
Markets

BTIG starts Akoya Biosciences at buy; PT $16

BTIG launched coverage of Akoya Biosciences (NASDAQ:AKYA) with a “buy” rating and $16 price target. The stock closed at $9.29 on June 21. Akoya is a rapidly growing life sciences technology company that offers a...

June 22, 2022
NexImmune-Logo
Markets

BTIG starts NexImmune at buy; PT $5

BTIG initiated coverage of NexImmune (NASDAQ:NEXI) with a “buy” rating and price target of $5. The stock closed at $2.28 on May 31. NexImmune exploits signals naturally provided by dendritic cells (DCs) to activate...

May 31, 2022
Liquidia Logo
Markets

BTIG starts Liquidia at buy; PT $14 

BTIG initiated coverage of Liquidia (NASDAQ:LQDA) with a “buy” rating and $14 price target. The stock closed at $4.07 on May 27. Analyst Julian Harrison writes that Liquidia has brought its lead candidate, YUTREPIA, to...

May 31, 2022